Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 57, 2022 - Issue 7
Submit an article Journal homepage
240
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Dili is rare amongst patients without liver metastases receiving cancer treatment in Iceland: a population-based cohort study

H. K. Björnssona Division of Gastroenterology and Hepatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland;b Department of Internal Medicine, Division of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg, Sweden;c Faculty of Medicine, University of Iceland, Reykjavik, IcelandCorrespondence[email protected]
View further author information
,
A. Sverrisdottird Department of Oncology, Landspitali - The National University Hospital of Iceland, Reykjavik, IcelandView further author information
&
E. S. Björnssona Division of Gastroenterology and Hepatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland;c Faculty of Medicine, University of Iceland, Reykjavik, IcelandView further author information
Pages 856-861 | Received 21 Nov 2021, Accepted 30 Jan 2022, Published online: 09 Feb 2022

References

  • Hoofnagle JH, Bjornsson ES. Drug-induced liver injury - types and phenotypes. N Engl J Med. 2019;381(3):264–273.
  • Dhanasekaran R, Kwo PY. The liver in oncology. Clin Liver Dis. 2017;21(4):697–707.
  • Bjornsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. Hepatology. 2016;63(2):590–603.
  • Bahirwani R, Reddy KR. Drug-induced liver injury due to cancer chemotherapeutic agents. Semin Liver Dis. 2014;34(2):162–171.
  • Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 2013;36(7):491–503.
  • Johncilla M, Misdraji J, Pratt DS, et al. Ipilimumab-associated hepatitis: Clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol. 2015;39(8):1075–1084.
  • Huffman BM, Kottschade LA, Kamath PS, et al. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol. 2018;41(8):760–765.
  • Miller ED, Abu-Sbeih H, Styskel B, et al. Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors. Am J Gastroenterol. 2020;115(2):251–261.
  • Azad A, Chang P, Devuni D, et al. Real world experience of drug induced liver injury in patients undergoing chemotherapy. J Clin Gastroenterol Hepatol. 2018;02(03):1–14.
  • Sigurdardottir LG, Jonasson JG, Stefansdottir S, et al. Data quality at the icelandic cancer registry: comparability, validity, timeliness and completeness. Acta Oncol. 2012;51(7):880–889.
  • Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. IJMS. 2015;17(1):14.
  • Common Terminology Criteria for Adverse Events (CTCAE).v.5.0. 2017. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50.
  • Fontes-Sousa M, Magalhães H, da Silva FC, et al. Stauffer's syndrome: a comprehensive review and proposed updated diagnostic criteria. Urol Oncol. 2018;36(7):321–326.
  • Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–1425.
  • De Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004;58(1):71–80.
  • Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with Drug-Induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340–1352.e7.
  • De Valle MB, Av Klinteberg V, Alem N, et al. Drug-induced liver injury in a swedish university hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24(8):1187–1195.
  • Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–455.
  • Shantakumar S, Landis S, Lawton A, et al. Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort. Regul Toxicol Pharmacol. 2016;77:257–262.
  • Weil JG, Bains C, Linke A, et al. Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease. Regul Toxicol Pharmacol. 2008;52(2):85–88.
  • Ulcickas Yood M, Bortolini M, Casso D, et al. Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system. Pharmacoepidemiol Drug Saf. 2015;24(4):427–434.
  • Tsung I, Dolan R, Lao CD, et al. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. Aliment Pharmacol Ther. 2019;50(7):800–808.
  • Powles T, Bracarda S, Chen M, et al. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and Meta-analysis of clinical trials in advanced cancer patients. Eur J Cancer. 2015;51(10):1293–1302.
  • Klempner SJ, Choueiri TK, Yee E, et al. Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients. J Clin Oncol. 2012;30(27):e264–e268.
  • Xu CF, Johnson T, Wang X, et al. HLA-B*57:01 confers susceptibility to Pazopanib-Associated liver injury in patients with cancer. Clin Cancer Res. 2016;22(6):1371–1377.
  • Finnsdottir S, Sverrisdottir A, Björnsson ES. Hepatotoxicity associated with ribociclib among breast cancer patients. Acta Oncol. 2021;60(2):195–198.
  • Kristinsdóttir H, Löve A, Bjornsson ES. Hepatitis A in Iceland. Laeknabladid. 2018;104(3):127–131.
  • Love A, Bjornsdottir TB, Olafsson S, et al. Low prevalence of hepatitis E in Iceland: a seroepidemiological study. Scand J Gastroenterol. 2018;53(3):293–296.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.